Madrigal Pharmaceuticals
MDGL
257 hedge funds and large institutions have $4.77B invested in Madrigal Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 87 increasing their positions, 83 reducing their positions, and 43 closing their positions.
26% more call options, than puts
Call options by funds: $208M | Put options by funds: $165M
5% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 83
2% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 43
0% more funds holding
Funds holding: 257 → 257 (0)
2.89% less ownership
Funds ownership: 107.33% → 104.43% (-2.9%)
25% less capital invested
Capital invested by funds: $6.41B → $4.77B (-$1.63B)
36% less funds holding in top 10
Funds holding in top 10: 14 → 9 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
+$49.1M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$47M |
| 3 |
State Street
Boston,
Massachusetts
|
+$36.6M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$20.1M |
| 5 |
RI
RTW Investments
New York
|
+$19.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$74.1M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$41.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$32M |
| 4 |
AC
Armistice Capital
New York
|
-$25.6M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$17.8M |
MDGL Hedge Fund Activity: Q3 2024 in Review
257 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q3 2024, worth a combined $4.77B — down 25% from $6.41B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new MDGL positions and 43 closed out — a net gain of 1 holder — while 87 added to existing stakes and 83 trimmed.
The largest buyer was Paulson & Co, adding an estimated $49.1M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $74.1M sold.
- 257 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $4.77B of Madrigal Pharmaceuticals stock for Q3 2024, down 25% quarter-over-quarter.
- 44 funds opened new Madrigal Pharmaceuticals positions in Q3 2024 and 43 closed out, a net change of +1 holder.
- The largest Madrigal Pharmaceuticals buyer in Q3 2024 was Paulson & Co, an estimated $49.1M added.
- The largest Madrigal Pharmaceuticals seller in Q3 2024 was Perceptive Advisors, an estimated $74.1M sold.
Based on aggregated 13F filings for Q3 2024.